Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Seegene Inc    A096530   KR7096530001

SEEGENE INC

(A096530)
  Report
 SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials
Sales 2020 1 039 B 0,94 B 0,94 B
Net income 2020 500 B 0,45 B 0,45 B
Net cash position 2020 410 B 0,37 B 0,37 B
P/E ratio 2020 10,0x
Yield 2020 0,05%
Sales 2021 1 093 B 0,99 B 0,99 B
Net income 2021 513 B 0,46 B 0,46 B
Net cash position 2021 864 B 0,78 B 0,78 B
P/E ratio 2021 9,79x
Yield 2021 0,10%
Capitalization 4 977 B 4 493 M 4 495 M
EV / Sales 2020 4 790x
EV / Sales 2021 4 552x
Nbr of Employees 216
Free-Float 67,3%
More Financials
Company
Seegene, Inc. is a Korea-based company engaged in the development, manufacturing and distribution of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP)... 
More about the company
Notations Surperformance© of Seegene Inc
Trading Rating : Investor Rating :
More Ratings
All news about SEEGENE INC
09/16Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
09/08SEEGENE : introduces a High-throughput 8-plex Test for Flu A, Flu B, RSV and COV..
AQ
08/13SEEGENE : South Korean COVID-19 test kit maker Seegene posts second-quarter prof..
RE
07/13Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
06/04Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
05/27Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
05/18SEEGENE : Exports 10 million Corona Tests to Brazil
AQ
05/14Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
05/08Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
05/05Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
05/02COVID-19 : More testing kits desperately needed - NCDC
AQ
04/28COVID-19 : More testing kits desperately needed - NCDC
AQ
04/27Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
04/27QIAGEN N : Govt's Dilemma - Can Lockdown Ease Amidst Rising Deaths and Spread of..
AQ
04/27QIAGEN N : COVID-19 - More Testing Kits Desperately Needed - NCDC
AQ
More news
News in other languages on SEEGENE INC

- No features available -

More news
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 330 560,00 KRW
Last Close Price 191 500,00 KRW
Spread / Highest target 125%
Spread / Average Target 72,6%
Spread / Lowest Target 39,4%
EPS Revisions
Managers
NameTitle
Jong-Yoon Chun Chief Executive Officer & Director
Jung-Yong Kim Director & Head-Finance
Kyung-Jun Chun Director
Hong-Il Yoon Independent Director
Jin-Soo Choi Director & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SEEGENE INC4 408
EXACT SCIENCES CORPORATION30.90%19 252
GUARDANT HEALTH, INC.55.00%12 109
INVITAE CORPORATION207.81%8 773
ADAPTIVE BIOTECHNOLOGIES CORPORATION61.16%6 595
IOVANCE BIOTHERAPEUTICS, INC.40.21%5 693